GALE Galena Biopharma, Inc.

0.62
0  -1%
Previous Close 0.63
Open 0.62
Price To book 0.33
Market Cap 22.36M
Shares 35,921,000
Volume 413,282
Short Ratio 2.55
Av. Daily Volume 2,396,800

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial terminated due to poor efficacy.
NeuVax (E75) - PRESENT
Low-to-intermediate HER2+ breast cancer
GALE-301 Phase 2a primary analysis presented at ASCO 2016.
GALE-301/302
Ovarian cancer
Phase 2 planned.
NeuVax
Gastric cancer
Phase 2b trial ongoing. Interim efficacy analysis due by the end of 2017. DSMB recommended trial to continue - February 6, 2017.
NeuVax in combination with Herceptin
Breast cancer
Phase 3 trial to be initiated 2Q 2017.
GALE-401
Essential Thrombocythemia (ET)
Phase 2 trial initiation announced December 14, 2016.
NeuVax
Ductal Carcinoma in Situ (DCIS)

Latest News

  1. Zacks.com featured highlights: Galena Biopharma, EVINE Live, Sanchez Production Partners, Bazaarvoice and Avon Products
  2. Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
  3. DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
  4. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline - April 14, 2017
  5. FRIDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  6. GALE APRIL 14 ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action - GALE
  7. For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
  8. SEC Targets Fraud on Stock Tip-Sheet Websites
  9. 4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
  10. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Galena Biopharma, Inc. to Contact the Firm
  11. DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  12. Deadline Alert: GPM Reminds Investors of the April 14 Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
  13. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017
  14. Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy
  15. DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Galena Biopharma, Inc. To Contact The Firm
  16. APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
  17. April 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Galena Biopharma, Inc. Investors of Upcoming Lead Plaintiff Deadline
  18. Galena's Breast Cancer Drug Combo Deemed Safe
  19. Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
  20. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm